27 June 2026 in SSRN Electronic Journal
Background: Gamabufotalin (Ga) is a primary bioactive bufadienolide extracted from Venenum Bufonis. It has been identified to exert anti-fibrotic and anti-inflammatory properties; however, its anti-fibrotic effect and underlying mechanism in heart failure (HF) remain undetermined.Purpose: This study aimed to evaluate the cardioprotective and anti-fibrotic properties of Ga in LADL-induced HF rats and isoproterenol (ISO)-induced HF mice. Furthermore, the molecular target and signaling mechanisms associated with Ga were investigated.Methods: In vivo cardiac function and fibrosis rate were assessed by echocardiography, histopathology, and Western blotting. For in vitro analysis, primary cardiac fibroblasts (CFs) were first stimulated with TGF-β1 and then evaluated for proliferation and migration using CCK-8, EdU, wound healing, and Transwell assays. Molecular docking and rescue assays were carried out using the TGFBR1 agonist SRI. Moreover, a Smad2/3 nuclear translocation assay was performed to identify the key target and mechanism.Results: The data revealed that Ga significantly improved cardiac function, alleviated myocardial hypertrophy and fibrosis, and inhibited activation of TGFBR1/Smad signaling in two HF models. In vitro, Ga (20 nM) inhibited TGF-β1-induced CF proliferation and migration, decreased Smad2/3 phosphorylation and nuclear translocation, and downregulated fibrotic markers. Ga directly targeted TGFBR1, whereas its anti-fibrotic effects were reversed by SRI-mediated TGFBR1 activation.Conclusion: This study revealed that Ga alleviates myocardial fibrosis and improves heart function by directly suppressing TGFBR1 and blocking downstream Smad2/3 signaling. These results suggest that Ga could serve as an anti-fibrotic agent for HF and provide pharmacological evidence for the modern application of toad venom–derived compounds.